Bromide

Bromide

SCHEMBL3276906

Br.Oc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1O

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ADRB2 known ✓ P07550 5/20 0.72
ADRB1 known ✓ P08588 1/20 0.68
DRD2 P14416 2/20 0.97
DRD4 P21917 2/20 0.97
MEN1 O00255 1/20 0.97
ABL1 P00519 1/20 0.97
ALPL P05186 1/20 0.97
GAA P10253 1/20 0.97
KMT2A Q03164 1/20 0.97
RIN1 Q13671 1/20 0.97
KDM1A O60341 1/20 0.77
TBXA2R P21731 7/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221137 0.99 DRD2 (1.00) DRD2DRD4MEN1ABL1ALPL
SCHEMBL29375567 0.99 DRD2 (1.00) DRD2DRD4MEN1ABL1ALPL
SCHEMBL29373547 0.99 DRD2 (1.00) DRD2DRD4MEN1ABL1ALPL
SCHEMBL16602137 0.99 DRD2 (1.00) DRD2DRD4MEN1ABL1ALPL
(+)-Higenamine SCHEMBL5898932 0.89 DRD2 (0.97) DRD2DRD4MEN1ABL1ALPL
(-)-Higenamine SCHEMBL5898916 0.89 DRD2 (0.97) DRD2DRD4MEN1ABL1ALPL
SCHEMBL13686544 0.88 DRD2 (0.80) DRD2DRD4MEN1ABL1ALPL
SCHEMBL16281797 0.88 DRD2 (0.80) DRD2DRD4MEN1ABL1ALPL
(-)-Higenamine SCHEMBL5898911 0.87 DRD2 (1.00) DRD2DRD4MEN1ABL1ALPL
(+)-Higenamine SCHEMBL5898913 0.87 DRD2 (1.00) DRD2DRD4MEN1ABL1ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1664262-A2 THE USE OF LABIATAE HERB PREPARATIONS FOR FOAM ENCHANCEMENT OF BEVERAGES Kalamazoo Holdings, Inc. (US) 2006-06-07 EP claimed
US-20050106306-A1 Use of Labiatae herb preparations for foam enhancement of malt beverages KALAMAZOO HOLDINGS, INC. 2005-05-19 US claimed
WO-2005028610-A2 THE USE OF LABIATAE HERB PREPARATIONS FOR FOAM ENCHANCEMENT OF BEVERAGES KALAMAZOO HOLDINGS, INC. (US) 2005-03-31 WO claimed
US-6562836-B1 Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes QUEEN'S UNIVERSITY OF KINGSTON (CA) 2003-05-13 US claimed
EP-0667245-A1 Recording sheets containing alcohols and saccharides XEROX CORPORATION (US) 1995-08-16 EP claimed
WO-2014104408-A1 BEER FLAVORED CARBONATED BEVERAGE KAO CORPORATION (JP) 2014-07-03 WO disclosed
EP-1664262-B1 THE USE OF LABIATAE HERB PREPARATIONS FOR FOAM ENCHANCEMENT OF BEVERAGES KALAMAZOO HOLDINGS INC (US) 2010-06-30 EP disclosed
US-7629400-B2 Image making medium HYMAN SYDNEY 2009-12-08 US disclosed
WO-2008021210-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS COMBINATORX, INCORPORATED (US) 2008-02-21 WO disclosed
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders CHDI, INCORPORATED 2008-02-21 US disclosed
EP-1664262-A2 THE USE OF LABIATAE HERB PREPARATIONS FOR FOAM ENCHANCEMENT OF BEVERAGES Kalamazoo Holdings, Inc. (US) 2006-06-07 EP disclosed
US-20050106306-A1 Use of Labiatae herb preparations for foam enhancement of malt beverages KALAMAZOO HOLDINGS, INC. 2005-05-19 US disclosed
WO-2005028610-A2 THE USE OF LABIATAE HERB PREPARATIONS FOR FOAM ENCHANCEMENT OF BEVERAGES KALAMAZOO HOLDINGS, INC. (US) 2005-03-31 WO disclosed
US-20030035917-A1 Image making medium HYMAN SYDNEY (US) 2003-02-20 US disclosed
EP-0667245-A1 Recording sheets containing alcohols and saccharides XEROX CORPORATION (US) 1995-08-16 EP disclosed
US-4279914-A 1-GLAUCINE OR TETRAHYDROXYAPORPHINE, ANTICOAGULANTS HERMANN GOTTFRIED SCHNABEL FA. (DE) 1981-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders HTT, SNCA, NLN ADRB2 4208/4885ADRB1 3918/4885DRD2 3226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.